Replies to post #68323 on Cytodyn Inc (CYDY)

[justdafactss]

Maybe patients are willing to risk a low percentage of possible side effects to survive right now today by using a better drug therapy than leronlimab.

Because leronlimab is still being studied, information on possible side effects of the drug is not complete. As testing of leronlimab continues, additional information on possible side effects will be gathered.
https://aidsinfo.nih.gov/drugs/423/leronlimab/0/patient

Thus the media attention Actemra is receiving.